A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer

Mustacchi, Giorgio; Muggia, M.; Milani, Stefano; Ceccherini, Rita; Leita, M. L.; Dellach, C.

doi:10.1093/annonc/mdf290

Cited by 20 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our series was commenced following evidence of good tolerance to MVP in lung cancer patients (Ellis et al, 1995), and shows very similar results to those reported above (Vassilomanolakis et al, 2000;Mustacchi et al, 2002). An ORR of 32% in a population of frequently heavily pretreated patients (92% of patients previously treated with anthracyclines and 28% with taxanes) is an encouraging result.…”

Section: Discussionsupporting

confidence: 79%

“…Carboplatin has been tested in the same first-line setting and shown better tolerability in some studies, although less convincing results in terms of response rate (Kolaric and Vukas, 1991;Brambilla et al, 1993). Two recent reports showed that cisplatin in combination with vinka-alkaloids may be a very well-tolerated regimen as an alternative to taxanes after anthracyclines failure (Vassilomanolakis et al, 2000;Mustacchi et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

“…A number of previous studies (Kolaric and Roth, 1983;Sledge et al, 1988;Smith and Talbot, 1992) have demonstrated the efficacy of cisplatin-based chemotherapy regimens both in previously untreated patients with metasatic breast cancer, and following anthracycline failure (Vassilomanolakis et al, 2000;Mustacchi et al, 2002). However, the widespread use of platinum-based treatments has been undermined by the alleged lower tolerability of these regimens and the requirement for prolonged infusion protocols.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer

et al. 2005

View full text Add to dashboard Cite

This phase II study assessed the clinical efficacy and tolerability of a combination of mitomycin C, vinblastine and cisplatin in patients with metastatic breast cancer (MBC) previously treated with chemotherapy. A total of 87 patients with MBC, most of whom had been exposed to anthracyclines (92%) and/or taxanes (29%) in the adjuvant and/or metastatic setting, were treated with mitomycin C (8 mg m À2 day 1 cycles 1, 2, 4 and 6), vinblastine (6 mg m À2 day 1) and cisplatin (50 mg m À2 day 1) repeated each 21 days for a maximum of six cycles. The overall response rate (ORR) was 32% (95% CI: 22 -42%) with 31% partial response (PR) and one complete response (CR). Stable disease (SD) rate was 21% (95% CI: 12 -29%). There was no statistically significant difference in the ORR when MVP was given as the first-line treatment for MBC vs second or subsequent line (38 vs 30%, P ¼ 0.6), or between patients with an early (o6 months) vs late (46 months) relapse post-anthracyclines (30 vs 52%, P ¼ 0.3). Toxicity profile was mild. This platinum-based chemotherapy is an effective, well-tolerated and low-cost regimen for patients with MBC, including those pretreated with anthracyclines.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Cisplatin is a first-line therapy for metastatic breast cancer. Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer, and preclinical data support synergy of the combination [14]. Cisplatin is one of the major chemotherapeutic weapons used against different human cancers, although its mechanism of apoptosis induction is not fully understood.…”

Section: Discussionmentioning

confidence: 99%

Cisplatin Induces Up-Regulation of KAI1, a Metastasis Suppressor Gene, in MCF-7 Breast Cancer Cell Line

Mokhtari¹,

Akbarzadeh²,

Hashemi³

et al. 2012

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…A large number of phase II trials have been performed which have generally shown encouraging activity with an acceptable safety profile ( [80][81][82][83] and Capecitabine, 84-88 which will be separately discussed. Several triplets have also been investigated but increased toxicity should be expected.…”

Section: Combination Regimens With Vinorelbinementioning

confidence: 99%

A Review of Vinorelbine in the Treatment of Advanced Breast Cancer

Brunello

Roma

Basso

et al. 2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Abstract:Vinorelbine is a semi-synthetic vinca alkaloid that has been shown active in many tumor types and is currently registered for the treatment of advanced breast cancer (ABC) and non-small cell lung cancer (NSCLC), and it is used in other cancer type such as prostate cancer, lymphomas, gynecologic malignancies. This agent has a generally favorable safety profile, and may be suitable for use in special populations such as the elderly and/or frail patient. However, with the taxanes established as standard second line treatment for ABC after failure of an anthracycline, Vinorelbine has been generally relegated for use as third line therapy, in competition with the oral compound Capecitabine. Combination regimens of Vinorelbine and Gemcitabine have been indeed widely studied, and have been demonstrated to be safe and effective. More recently, the exciting results observed with the combination of Vinorelbine and Trastuzumab in patients with Her-2 overexpressing tumors, as well as the development of a reliable formulation and revised schedule of oral Vinorelbine appear to have revived the interest in this compound in the management of this disease. Yet, data from properly designed randomized clinical trials are eagerly awaited to confirm the amount of available data which are mostly based on phase II studies.

show abstract

A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer

Abstract: Cisplatin plus vinorelbine is active and tolerable in metastatic breast cancer, in untreated and pretreated patients.

Cited by 20 publications

References 20 publications

Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer

Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer

Cisplatin Induces Up-Regulation of KAI1, a Metastasis Suppressor Gene, in MCF-7 Breast Cancer Cell Line

A Review of Vinorelbine in the Treatment of Advanced Breast Cancer

Contact Info

Product

Resources

About